Tilorone confers robust <em>in vitro</em> and <em>in vivo</em> antiviral effects against severe fever with thrombocytopenia syndrome virus

Jingjing Yang; Yunzheng Yan; Qingsong Dai; Jiye Yin; Lei Zhao; Yuexiang Li; Wei Li; Wu Zhong; Ruiyuan Cao; Song Li

doi:10.1016/j.virs.2022.01.014

February 2022

Jingjing Yang, Yunzheng Yan, Qingsong Dai, Jiye Yin, Lei Zhao, Yuexiang Li, Wei Li, Wu Zhong, Ruiyuan Cao and Song Li. Tilorone confers robust in vitro and in vivo antiviral effects against severe fever with thrombocytopenia syndrome virus[J]. Virologica Sinica, 2022, 37(1): 145-148. doi: 10.1016/j.virs.2022.01.014

Citation: Jingjing Yang, Yunzheng Yan, Qingsong Dai, Jiye Yin, Lei Zhao, Yuexiang Li, Wei Li, Wu Zhong, Ruiyuan Cao, Song Li. Tilorone confers robust in vitro and in vivo antiviral effects against severe fever with thrombocytopenia syndrome virus .VIROLOGICA SINICA, 2022, 37(1) : 145-148. http://dx.doi.org/10.1016/j.virs.2022.01.014

替洛隆在体内外均对严重发热伴血小板减少综合征病毒具有显著抑制作用

杨晶晶 ^a,b ,
闫赟政 ^b ,
代青松 ^b ,
尹纪业 ^b ,
赵磊 ^b ,
李月香 ^b ,
李微 ^b ,
钟武 ^b ,
曹瑞源 ^b,, ,
李松 ^a,b,,

海南大学药学院
军事医学研究院

通讯作者： 曹瑞源, 21cc@163.com; 李松, lis.lisong@gmail.com
收稿日期： 2021-09-08
录用日期： 2021-11-25

摘要

严重发热伴血小板减少综合征病毒（SFTSV）是一种新型病原体，于2009年在我国首次分离得到。近年来，该病在东亚地区多次暴发，但尚无疫苗或药物获批用于治疗这一新型布尼亚病毒感染。本研究中，我们首先构建了一个基于细胞病变效应（cytopathological effect，CPE）的高通量药物筛选模型。在此基础上，发现已上市药物替洛隆（Tilorone）具有良好的抗SFTSV活性。经进一步验证，我们发现替洛隆在体外和体内均可以通过激活天然免疫反应抑制SFTSV感染，并对SFTSV感染表现出良好预防作用。
- 严重发热伴血小板减少综合征病毒
- , 替洛隆
- , 抗病毒活性
- , 预防病毒感染

Tilorone confers robust in vitro and in vivo antiviral effects against severe fever with thrombocytopenia syndrome virus

Jingjing Yang ^a,b ,
Yunzheng Yan ^b ,
Qingsong Dai ^b ,
Jiye Yin ^b ,
Lei Zhao ^b ,
Yuexiang Li ^b ,
Wei Li ^b ,
Wu Zhong ^b ,
Ruiyuan Cao ^b,, ,
Song Li ^a,b,,

a School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China
b National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China

Corresponding author: Ruiyuan Cao, 21cc@163.com Song Li, lis.lisong@gmail.com
Received Date: 08 September 2021
Accepted Date: 25 November 2021

Abstract

Severe fever with thrombocytopenia syndrome virus (SFTSV), an emerging pathogen, is a tick-borne bunyavirus belonging to the genus Bandavirus in the family Phenuiviridae (Kuhn et al., 2020). This pathogen was first identified in China during the heightened surveillance of acute febrile illness in 2009, and has been reported to cause several outbreaks in eastern Asia areas, including China, Japan, and Korea (Yu et al., 2011). Besides, Vietnam has also reported several confirmed SFTS cases (Tran et al., 2019). The mortality rate in hospitalised patients with SFTSV infection is up to 10%–30%. Moreover, SFTSV has been reported to possibly transmitted by the contact of body fluids from person-to-person, and extensive SFTSV contamination was detected in the patient rooms (Kim et al., 2015). These reports suggest that more stringent isolation measures are needed for the prevention of massive SFTSV outbreak.

References
1. Baba M, Toyama M, Sakakibara N, Okamoto M, Arima N, Saijo M. Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors. Antivir Chem Chemother. 2017;25:83-89.
2. Binder M, Kochs G, Bartenschlager R, Lohmann V. Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology. 2007;46:1365-1374.
3. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76:13001-13014.
4. Ekins S, Lane T, Madrid P. Tilorone: a broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond. Pharm Res. 2020;37:71.
5. Kuhn JH, Adkins S, Alioto D, Alkhovsky SV, Amarasinghe GK, Anthony SJ, Avsic-Zupanc T, Ayllon MA, Bahl J, Balkema-Buschmann A, Ballinger MJ, Bartonicka T, Basler C, Bavari S, Beer M, Bente DA, Bergeron E, Bird BH, Blair C, Blasdell KR, Bradfute SB, Breyta R, Briese T, Brown PA, Buchholz UJ, Buchmeier MJ, Bukreyev A, Burt F, Buzkan N, Calisher CH, Cao M, Casas I, Chamberlain J, Chandran K, Charrel RN, Chen B, Chiumenti M, Choi IR, Clegg JCS, Crozier I, da Graca JV, Dal Bo E, Davila AMR, de la Torre JC, de Lamballerie X, de Swart RL, Di Bello PL, Di Paola N, Di Serio F, Dietzgen RG, Digiaro M, Dolja VV, Dolnik O, Drebot MA, Drexler JF, Durrwald R, Dufkova L, Dundon WG, Duprex WP, Dye JM, Easton AJ, Ebihara H, Elbeaino T, Ergunay K, Fernandes J, Fooks AR, Formenty PBH, Forth LF, Fouchier RAM, Freitas-Astua J, Gago-Zachert S, Gao GF, Garcia ML, Garcia-Sastre A, Garrison AR, Gbakima A, Goldstein T, Gonzalez JJ, Griffiths A, Groschup MH, Gunther S, Guterres A, Hall RA, Hammond J, Hassan M, Hepojoki J, Hepojoki S, Hetzel U, Hewson R, Hoffmann B, Hongo S, Hoper D, Horie M, Hughes HR, Hyndman TH, Jambai A, Jardim R, Jiang D, Jin Q, Jonson GB, Junglen S, Karadag S, Keller KE, Klempa B, Klingstrom J, Kobinger G, Kondo H, Koonin EV, Krupovic M, Kurath G, Kuzmin IV, Laenen L, Lamb RA, Lambert AJ, Langevin SL, Lee B, Lemos ERS, Leroy EM, Li D, Lǐ J, Liang M, Liu W, Liu Y, Lukashevich IS, Maes P, Marciel de Souza W, Marklewitz M, Marshall SH, Martelli GP, Martin RR, Marzano SL, Massart S, McCauley JW, Mielke-Ehret N, Minafra A, Minutolo M, Mirazimi A, Muhlbach HP, Muhlberger E, Naidu R, Natsuaki T, Navarro B, Navarro JA, Netesov SV, Neumann G, Nowotny N, Nunes MRT, Nylund A, OEkland AL, Oliveira RC, Palacios G, Pallas V, Palyi B, Papa A, Parrish CR, Pauvolid-Correa A, Paweska JT, Payne S, Perez DR, Pfaff F, Radoshitzky SR, Rahman AU, Ramos-Gonzalez PL, Resende RO, Reyes CA, Rima BK, Romanowski V, Robles Luna G, Rota P, Rubbenstroth D, Runstadler JA, Ruzek D, Sabanadzovic S, Salat J, Sall AA, Salvato MS, Sarpkaya K, Sasaya T, Schwemmle M, Shabbir MZ, Shi X, Shi Z, Shirako Y, Simmonds P, Sirmarova J, Sironi M, Smither S, Smura T, Song JW, Spann KM, Spengler JR, Stenglein MD, Stone DM, Strakova P, Takada A, Tesh RB, Thornburg NJ, Tomonaga K, Tordo N, Towner JS, Turina M, Tzanetakis I, Ulrich RG, Vaira AM, van den Hoogen B, Varsani A, Vasilakis N, Verbeek M, Wahl V, Walker PJ, Wang H, Wang J, Wang X, Wang LF, Wei T, Wells H, Whitfield AE, Williams JV, Wolf YI, Wu Z, Yang X, Yang X, Yu X, Yutin N, Zerbini FM, Zhang T, Zhang Y, Zhou G, Zhou X. 2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Arch Virol. 2020;165:3023-3072.
6. Kim WY, Choi W, Park SW, Wang EB, Lee WJ, Jee Y, Lim KS, Lee HJ, Kim SM, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. Nosocomial transmission of severe fever with thrombocytopenia syndrome in Korea. Clin Infect Dis. 2015;60:1681-1683.
7. Li H, Jiang X, Cui N, Yuan C, Zhang S, Lu Q, Yang Z, Xin Q, Song Y, Zhang X, Liu H, Du J, Fan X, Yuan L, Yuan Y, Wang Z, Wang J, Zhang L, Zhang D, Wang Z, Dai K, Bai J, Hao Z, Fan H, Fang L, Xiao G, Yang Y, Peng K, Wang H, Li J, Zhang L, Liu W. Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome. Signal Transduct Target Ther. 2021;6:145.
8. Li H, Lu Q, Xing B, Zhang S, Zhang S, Liu K, Du J, Li X, Cui N, Yang Z, Wang L, Hu J, Cao W, Liu W. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011-17: a prospective observational study. Lancet Infect Dis. 2018;18:1127-1137.
9. Li H, Zhang L, Li S, Zhang S, Wan W, Zhang Y, Xin Q, Dai K, Hu Y, Wang Z, Zhu X, Fang Y, Cui N, Zhang P, Yuan C, Lu Q, Bai J, Deng F, Xiao G, Liu W, Peng K. Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality. Cell Res. 2019;29:739-753.
10. Li X, Deng Y, Zhao H, Ye Q, Wang H, Li S, Zhu S, Shi P, Qin E, Zhang B, Qin C. Noninvasive bioluminescence imaging of dengue virus infection in the brain of A129 mice. Appl Microbiol Biotechnol. 2013;97:4589-4596.
11. Liu W, Lu Q, Cui N, Li H, Wang L, Liu K, Yang Z, Wang B, Wang H, Zhang Y, Zhuang L, Hu C, Yuan C, Fan X, Wang Z, Zhang L, Zhang X, Walker D, Cao W. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in China who had severe fever with thrombocytopenia syndrome. Clin Infect Dis. 2013;57:1292-1299.
12. Liu S, Liu H, Zhang K, Li X, Duan Y, Wang Z, Wang T. Proteasome inhibitor PS-341 effectively blocks infection by the severe fever with thrombocytopenia syndrome virus. Virol Sin. 2019;34:572-582.
13. Ning Y, Mo Q, Feng K, Min Y, Li M, Hou D, Peng C, Zheng X, Deng F, Hu Z, Wang H. Interferon-γ-directed inhibition of a novel high-pathogenic phlebovirus and viral antagonism of the antiviral signaling by targeting STAT1. Front Immunol. 2019;10:1182.
14. Tran XC, Yun Y, Van AL, Kim SH, Thao NTP, Man PKC, Yoo JR, Heo ST, Cho NH, Lee KH. Endemic severe fever with thrombocytopenia syndrome, Vietnam. Emerg Infect Dis. 2019;25:1029-1031.
15. Vartiainen V, Raula J, Bimbo LM, Viinamaki J, Backman JT, Ugur N, Kauppinen E, Sutinen E, Joensuu E, Koli K, Myllarniemi M. Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. Int J Pharm. 2018;544:121-128.
16. Xiao X, Wang C, Chang D, Wang Y, Dong X, Jiao T, Zhao Z, Ren L, Cruz C, Sharma L, Lei X, Wang J. Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2. Front Immunol. 2020;11:586572.
17. Yamada H, Taniguchi S, Shimojima M, Tan L, Kimura M, Morinaga Y, Fukuhara T, Matsuura Y, Komeno T, Furuta Y, Saijo M, Tani H. M segment-based minigenome system of severe fever with thrombocytopenia syndrome virus as a tool for antiviral drug screening. Viruses. 2021;13:1061.
18. Yang J, Xu Y, Yan Y, Li W, Zhao L, Dai Q, Li Y, Li S, Zhong J, Cao R, Zhong W. Small molecule inhibitor of ATPase activity of HSP70 as a broad-spectrum inhibitor against flavivirus infections. ACS Infect Dis. 2020;6:832-843.
19. Yu X, Liang M, Zhang S, Liu Y, Li J, Sun Y, Zhang L, Zhang Q, Popov VL, Li C, Qu J, Li Q, Zhang Y, Hai R, Wu W, Wang Q, Zhan F, Wang X, Kan B, Wang S, Wan K, Jing H, Lu J, Yin W, Zhou H, Guan X, Liu J, Bi Z, Liu G, Ren J, Wang H, Zhao Z, Song J, He J, Wan T, Zhang J, Fu X, Sun L, Dong X, Feng Z, Yang W, Hong T, Zhang Y, Walker DH, Wang Y, Li D. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364:1523-1532.
20. Yuan S, Chan JF, Ye Z, Wen L, Tsang T, Cao J, Huang J, Chan C, Chik K, Choi G, Cai J, Yin F, Chu H, Liang M, Jin D, Yuen K. Screening of an FDA-approved drug library with a two-tier system identifies an entry inhibitor of severe fever with thrombocytopenia syndrome virus. Viruses. 2019;11:385
Proportional views

Electronic Supplementary Material

10.1016j.virs.2022.01.014-ESM7.jpg
10.1016j.virs.2022.01.014-ESM3.jpg
10.1016j.virs.2022.01.014-ESM5.jpg
10.1016j.virs.2022.01.014-ESM6.jpg
10.1016j.virs.2022.01.014-ESM1.jpg
10.1016j.virs.2022.01.014-ESM2.jpg
10.1016j.virs.2022.01.014-ESM8.jpg
10.1016j.virs.2022.01.014-ESM9.docx
10.1016j.virs.2022.01.014-ESM4.jpg